Overweight and Obesity in People Living with HIV on Different Therapies
Author Information
Author(s): Jemal Mohammed, Adugna Adane, Getinet Mamaru, Baylie Temesgen, Waritu Nuredin Chura
Primary Institution: Debre Markos University, Ethiopia
Hypothesis
What is the prevalence of overweight and obesity among people living with HIV on dolutegravir- and efavirenz-based therapies?
Conclusion
Overweight and obesity are common among people living with HIV on antiretroviral therapy, with higher prevalence in those treated with dolutegravir compared to efavirenz.
Supporting Evidence
- The prevalence of overweight and obesity was 28.1% in the dolutegravir group and 15.6% in the efavirenz group.
- Older age, higher CD4 cell counts, and insufficient physical activity were significantly associated with overweight and obesity.
- Participants aged 40 years and older were nearly four times more likely to be overweight or obese.
Takeaway
Some people with HIV are gaining weight while on treatment, especially those taking a specific medicine called dolutegravir. It's important for doctors to help them manage their weight.
Methodology
A comparative cross-sectional study was conducted with 128 participants on dolutegravir and efavirenz therapies, collecting demographic and clinical data through questionnaires and analyzing it using logistic regression.
Potential Biases
Differences in the duration of HIV diagnosis and ART treatment between groups may introduce bias.
Limitations
The study's cross-sectional design limits causal inferences, and the sample was drawn from a single hospital, which may not represent the broader population.
Participant Demographics
Participants included adults aged 18 and older, with a significant portion being over 40 years old.
Statistical Information
P-Value
0.037
Confidence Interval
95% CI: 1.08–13.73
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website